#United States #Parker Waichman #Port Washington #Ozempic #NAION

Parker Waichman LLP Files Lawsuits for Eye Condition Linked to Ozempic

Parker Waichman LLP, a prominent legal firm, has initiated a series of lawsuits against the pharmaceutical company Novo Nordisk on behalf of individuals who have developed an irreversible eye condition known as NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) after using the medication Ozempic. The law firm has seen a surge in cases from patients prescribed Ozempic or its cousin Wegovy, both GLP-1 receptor agonists originally intended to manage Type 2 diabetes, that have now gained popularity for their weight loss benefits.

What is NAION?

NAION can result in partial or complete permanent vision loss in one or both eyes due to a disruption in blood flow to the optic nerve. The ramifications of this condition can be severe, and many who have been affected report sudden blindness and irreversible complications. With growing evidence linking Ozempic to serious ocular issues, the lawsuits aim to hold Novo Nordisk accountable for their failure to appropriately warn patients and healthcare providers about these risks.

Recent Developments in Lawsuits

On June 29 and June 30 of 2026, Parker Waichman filed lawsuits on behalf of residents from Georgia and California, respectively. Both plaintiffs alleged they experienced vision loss due to NAION, a condition highlighted in their legal complaints. This push for justice is not isolated; Parker Waichman continues to gather additional cases from various states across the country, stressing the urgency for those affected by similar outcomes to reach out for legal assistance.

Evidence Linking Ozempic to Eye Injuries

Research has indicated a disturbing correlation between semaglutide (the active ingredient in Ozempic and Wegovy) and the incidence of NAION. A pivotal study published in JAMA Ophthalmology in 2025 examined nine patients who reported optic nerve issues following GLP-1 medication usage. Alarmingly, findings from the Mass Eye and Ear Institute at Harvard revealed a fourfold increase in NAION risk among diabetic users of semaglutide, and a sevenfold increase for non-diabetic users seeking weight loss solutions. This emerging data raises concerns regarding the lack of adequate warnings from Novo Nordisk and the company's attempt to downplay the associated dangers of their products.

The Firm's Stance

Jason S. Goldstein, a Senior Litigation Counsel at Parker Waichman LLP, expressed his concern over the severe impacts of NAION, stating, "Despite the compelling evidence from multiple studies linking semaglutide to this devastating injury, Novo Nordisk continues to deny the reality of the situation. It is imperative that the company is held accountable for not providing adequate warnings to both consumers and medical professionals."

Seeking Justice for Victims

Parker Waichman LLP is now extending its services nationwide for those who have experienced vision loss related to the use of Ozempic or Wegovy. Potential claimants may be eligible for compensation covering medical expenses, lost wages, pain and suffering, and other damages incurred as a result of their condition.

Free Case Evaluations

If you or someone you know has suffered from sudden vision loss or optic nerve damage after using Ozempic or Wegovy, it's crucial to seek legal counsel. Parker Waichman LLP offers free, no-obligation case evaluations to help victims understand their rights and the potential for pursuing justice. You can contact the firm at 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com for more information on your legal options.

About Parker Waichman LLP

Parker Waichman LLP is recognized nationally for its commitment to advocating for victims affected by defective drugs, dangerous products, and corporate negligence. Their extensive experience in representing victims of eye injuries due to pharmaceutical negligence has resulted in billions of dollars secured in settlements and verdicts. With a proven track record, the firm continues to fight for accountability in the medical and pharmaceutical sectors.